Aurinia Pharmaceuticals(US:AUPH) ZACKS·2025-12-05 18:01Core Viewpoint - Aurinia Pharmaceuticals (AUPH) is identified as a promising momentum stock, currently holding a Momentum Style Score of B and a Zacks Rank of 2 (Buy) [3][4][12] Momentum Style Score - The Zacks Momentum Style Score incorporates price changes and earnings estimate revisions to evaluate stocks [2][9] - AUPH's shares have increased by 19.8% over the past quarter and 72.41% over the last year, significantly outperforming the S&P 500, which moved 5.77% and 13.9% respectively [7] Price Performance - AUPH shares are up 2.81% over the past week, while the Zacks Medical - Drugs industry has increased by 4.43% during the same period [6] - The monthly price change for AUPH is 9.75%, compared to the industry's 1.34% performance [6] Trading Volume - AUPH's average 20-day trading volume is 1,763,778 shares, indicating a bullish sign as it reflects current interest in the stock [8] Earnings Outlook - Over the past two months, 4 earnings estimates for AUPH have moved higher, with no downward revisions, increasing the consensus estimate from $0.62 to $0.78 [10] - For the next fiscal year, 4 estimates have also moved upwards without any downward revisions [10]